Verona Pharma PLC Verona to present RPL554 at the ATS Conference
May 04 2016 - 2:00AM
UK Regulatory
TIDMVRP
Verona Pharma plc
("Verona Pharma" or the "Company")
Verona to present clinical data on RPL554 at the ATS International Conference
04 May 2016, Cardiff - Verona Pharma plc (AIM: VRP.L), the drug development
company focused on first-in-class medicines to treat respiratory diseases,
today announces that it will present three abstracts at the American Thoracic
Society (ATS) 2016 International Conference in San Francisco, USA between 13-18
May. The abstracts will cover clinical data related to the Company's lead drug
RPL554, a novel inhaled PDE3/PDE4 inhibitor with both bronchodilator and
anti-inflammatory properties, currently in development as a nebulised treatment
for acute exacerbations in chronic obstructive pulmonary disease (COPD)
patients in a hospital or home-care setting.
All three posters support Verona Pharma's view that RPL554 could become an
important, novel and complementary inhaled medicine for the treatment of
respiratory diseases such as COPD, asthma, and cystic fibrosis.
All abstracts and details on timings can be accessed through the ATS website:
http://conference.thoracic.org/
The title, timing and location of the poster presentations are as follows:
Abstract ID 13130
Authors: L. Bjermer, J. Stewart, K. Abbott-Banner, K. Newman
Title: RPL554, a First-In-Class Dual Phosphodiesterase (PDE)3/4 Inhibitor,
Is Equi-Effective as a Bronchodilator to Maximal Doses of
Salbutamol in Asthmatics but with Fewer Adverse Events
Day/Date: SUNDAY, MAY 15, 2016
Location: Area A (Hall D) Moscone Centre (North Building) P36
Time: 9:00 AM-4:15 PM
Session: A31 - ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND
Session Type: Thematic Poster Session
Abstract ID 6811
Authors: D. Singh, K.H. Abbott-Banner, F. Reid, K. Newman
Title: A Phase I, Randomised, Double Blind, Placebo Controlled, Study To
Assess The Safety, Tolerability And Pharmacokinetics Of Multiple
Inhaled Doses Of RPL554 Administered By Nebuliser To Healthy Male
Subjects And Stable COPD Patients
Day/Date: WEDNESDAY, MAY 18, 2016
Location: Area A (Hall D) Moscone Centre (North Building) P71
Time: 9:00 AM-3:30 PM
Session: D37-COPD: DEVELOPMENTAL THERAPEUTICS
Session Type: Thematic Poster Session
Abstract ID 4841
Authors: D. Singh, K.H. Abbott-Banner, F. Reid, K. Newman
Title: A Phase I, Randomised, Double Blind, Placebo Controlled, Study To
Assess The Safety, Tolerability And Pharmacokinetics Of Single
Inhaled Doses Of The Dual Phosphodiesterase 3/4 (PDE3/4) Inhibitor
RPL554 Administered By Nebuliser To Healthy Male subjects
Day/Date: WEDNESDAY, MAY 18, 2016
Location: Area A (Hall D) Moscone Centre (North Building) P72
Time: 9:00 AM-3:30 PM
Session: D37-COPD: DEVELOPMENTAL THERAPEUTICS
Session Type: Thematic Poster Session
-ENDS-
About Verona Pharma
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase
2 trials as a nebulised treatment for acute exacerbations of COPD in the
hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and
therefore has both bronchodilator and anti-inflammatory effects, which are
essential to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of RPL554-containing
products to maximise its benefit to patients and its value. This includes the
very significant markets for COPD and asthma maintenance therapy. In addition,
the Company is exploring the potential of the drug in different diseases, such
as cystic fibrosis, where it is in pre-clinical testing and has received a
Venture and Innovation Award from the UK Cystic Fibrosis Trust.
About ATS International Conference
The ATS International Conference is the home of pulmonary, critical care, and
sleep professionals, from those in the earliest stages of their careers to
people with research or strides in clinical care, which has gained them
international recognition. Each year, nearly 14,000 of these professionals
choose to attend, present, and learn about the latest advances, meet with
colleagues from around the world, and strike new collaborations. It is truly
where today's science meets tomorrow's care.
The International Conference is also multidisciplinary. Clinicians and
researchers in many other fields attend the conference, thereby enriching
conversations that lead to insights that ultimately improve patient care. Among
the many other specialties represented in sessions at the International
Conference are:
Allergy/Immunology, Behavioural Science, Cardiology, Environmental and
Occupational Health, Infectious Disease, Paediatric, Pulmonary, Critical Care
and Sleep
Equally important, the ATS International Conference gathers the entire health
care team in one place to share ideas across these medical and scientific
disciplines. It is the ideal place for nurses, respiratory therapists, and
hospitalists to discuss their experiences, challenges, and research so that all
can learn about the latest advances in understanding pulmonary disease,
critical illness, and sleep disorders. And of course, the International
Conference is truly international: 40 percent of attendees arrive from
laboratories and patient care centres beyond the United States.
Further information on the conference can be accessed via the following
weblink: http://conference.thoracic.org/
For further information, please contact:
Verona Pharma plc Tel: +44 (0) 20 7863 3300
Jan-Anders Karlsson, CEO
N+1 Singer Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
FTI Consulting Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie Cuthbert/
Natalie Garland-Collins
END
(END) Dow Jones Newswires
May 04, 2016 02:00 ET (06:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
